Overview

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

Status:
Completed
Trial end date:
2006-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.
Phase:
Phase 3
Details
Lead Sponsor:
EMD Serono